Quoin Pharmaceuticals, Ltd. (QNRX)
| Market Cap | 8.51M +133.5% |
| Revenue (ttm) | n/a |
| Net Income | -16.99M |
| EPS | n/a |
| Shares Out | 1.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,833 |
| Open | 4.920 |
| Previous Close | 4.850 |
| Day's Range | 4.590 - 4.950 |
| 52-Week Range | 4.590 - 41.800 |
| Beta | 1.75 |
| Analysts | Strong Buy |
| Price Target | 29.75 (+530.3%) |
| Earnings Date | May 7, 2026 |
About QNRX
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company’s lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for QNRX stock is "Strong Buy." The 12-month stock price target is $29.75, which is an increase of 530.30% from the latest price.
News
Quoin Pharmaceuticals Earnings release: Q1 2026
Quoin Pharmaceuticals released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Quoin Pharmaceuticals Quarterly report: Q1 2026
Quoin Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 7, 2026.
Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results
– Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome – Submitted Application to Japanese MHLW for Orphan Drug Designation (ODD) for QRX003; MHLW Confir...
Quoin Pharmaceuticals initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of Quoin Pharmaceuticals (QNRX) with a Buy rating and $30 price target Quoin is a late-stage clinical specialty pharmaceutical company positioned to potentially delive...
Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026
ASHBURN, Va., April 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan...
CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs
Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications.
Quoin Pharmaceuticals provides regulatory update on QRX009 topical rapamycin
Quoin Pharmaceuticals (QNRX) provided a clinical and regulatory update for its QRX009 topical rapamycin development programs. The company is planning to initiate several investigator-led clinical stud...
Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs
Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications. Company to Initiate Investigator Led Clinical Study in Pachyonychia Congenita...
Quoin Pharmaceuticals price target raised to $35 from $25 at Alliance Global
Alliance Global raised the firm’s price target on Quoin Pharmaceuticals (QNRX) to $35 from $25 and keeps a Buy rating on the shares. The firm, which notes that its price…
Quoin Pharmaceuticals Annual report: Q4 2025
Quoin Pharmaceuticals has published its Q4 2025 annual report on March 26, 2026.
Quoin Pharmaceuticals Earnings release: Q4 2025
Quoin Pharmaceuticals released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
Quoin Pharmaceuticals Ltd – ADR trading resumes
09:38 EDT Quoin Pharmaceuticals (QNRX) Ltd – ADR trading resumes
Quoin Pharmaceuticals Ltd – ADR trading halted, volatility trading pause
09:33 EDT Quoin Pharmaceuticals (QNRX) Ltd – ADR trading halted, volatility trading pause
Quoin Pharmaceuticals provides update following QRX003 Type C meeting with FDA
Quoin Pharmaceuticals (QNRX) provided a clinical and regulatory update from its recent constructive Type C meeting with the FDA for its lead product candidate, QRX003, for the treatment of Netherton…
Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome
FDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S. FDA expressed openness to an alternative study design for Phase 3 that would likely not include a ...
Quoin Pharmaceuticals Slides: Corporate presentation
Quoin Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on March 25, 2026.
Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026
ASHBURN, Va., March 19, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan...
Quoin Pharmaceuticals receives U.S. Fast Track Designation to QRX003
Quoin Pharmaceuticals (QNRX) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to QRX003 lotion for the treatment of Netherton Syndrome, a rare and severe genetic...
Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome
— Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need —
Quoin Pharmaceuticals highlights continued growth of NETHERTON NOW program
In recognition of Rare Disease Day 2026, Quoin Pharmaceuticals (QNRX) highlighted the continued growth of its NETHERTON NOW awareness campaign, which seeks to amplify the voices of patients, caregiver...
Quoin Pharmaceuticals Ltd – ADR trading resumes
10:21 EST Quoin Pharmaceuticals (QNRX) Ltd – ADR trading resumes
Quoin Pharmaceuticals Ltd – ADR trading halted, volatility trading pause
10:11 EST Quoin Pharmaceuticals (QNRX) Ltd – ADR trading halted, volatility trading pause
Quoin announces submission to Japanese MHLW for ODD for QRX003
Quoin Pharmaceuticals (QNRX) announced that following a successful meeting with the Japanese MHLW that it has submitted an application for Orphan Drug Designation, ODD, for its lead product candidate,...
Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome
Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status
Quoin files Breakthrough Medicine Designation with SFDA for QRX003
Quoin Pharmaceuticals (QNRX) announced that it has filed an application for Breakthrough Medicine Designation with the Saudi Food and Drug Authority, SFDA, for QRX003. If granted, the designation will...